MENINGITIS VACCINE – MENINGOCOCCAL VACCINE – MENINGITIS VACCINATION – MENINGITIS IMMUNIZATION

 
FOR HEALTHCARE PROVIDERS
Meningococcal Disease
Why vaccinate adults against meningococcal disease?
  • About one in 10 people who get meningococcal disease will die from it, even with rapid and appropriate treatment.

  • Two in 10 survivors will have serious long-term and permanent sequelae including hearing loss, brain damage, renal failure, or limb amputations.

  • The early symptoms of meningitis infection might be mild and similar to symptoms of less severe infections, like the flu, which can lead to missed diagnosis.

View CDC immunization recommendations
 
Read More
Click the link below for more information on meningococcal disease:
  Meningococcal Disease
  Fact Sheet
 
 
Additional Resources
Learn more about NFID’s S.T.O.P. Meningitis! initiative:

Visit the website
 
Contact Us  |  About NFID  |  Call to Action  |  Supporting Organizations This website is supported by unrestricted educational grants from GlaxoSmithKline, Merck & Co., Pfizer Inc., and Sanofi Pasteur. NFID’s policies prohibit funders from controlling program content. This site reflects US immunization policy and is intended for US residents.